FAQ on ReAlta’s Pegtarazimod and Its Potential in Treating Newborn HIE

What is pegtarazimod (RLS-0071)?

Pegtarazimod (RLS-0071) is an anti-inflammatory peptide developed by ReAlta Life Sciences, showing potential in reducing brain inflammation in conditions like hypoxic ischemic encephalopathy (HIE).

Why is the study on pegtarazimod significant?

The study is significant because it demonstrates pegtarazimod’s ability to reduce key measures of brain inflammation in HIE, a condition with no current pharmacological intervention, suggesting a new treatment pathway.

How does pegtarazimod work in reducing brain inflammation?

Pegtarazimod reduces levels of resident microglia and neuroinflammatory factors like myeloperoxidase (MPO) and reactive oxygen species (ROS), which are associated with pathogenic neuroinflammation in HIE.

Who could benefit from pegtarazimod treatment?

Newborns suffering from hypoxic ischemic encephalopathy (HIE) and potentially patients with other neurodegenerative diseases like Alzheimer’s and Parkinson’s could benefit from pegtarazimod treatment.

When will pegtarazimod be available for clinical use?

ReAlta expects to report an interim clinical data readout in the second half of 2025, but availability for clinical use depends on further trials and regulatory approvals.

Where is the STAR trial for pegtarazimod being conducted?

The STAR trial is currently enrolling patients across 13 NICUs in the United States.

What are the implications of pegtarazimod’s preclinical findings?

The findings suggest pegtarazimod could offer a new pharmacological intervention for HIE by reducing detrimental microglial-mediated inflammation, beyond the current standard of care.

How does pegtarazimod compare to current HIE treatments?

Pegtarazimod demonstrated anti-inflammatory effects equivalent to therapeutic hypothermia, the current standard of care, and showed 6% greater neuron density compared to hypothermia treatment alone in the study.

Who should be contacted for more information on pegtarazimod?

For more information, interested parties can contact ReAlta Life Sciences through their website at https://realtalifesciences.com/.